Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. Imaging agents, such as fluoroethyltyrosine, may help doctors see the tumor better during a positron emission tomography (PET) scan.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Thomas Hope

Criteria

Inclusion Criteria:

• Age > 3 years.

• Presence or suspicion of intracranial neoplasm planning to undergo either biopsy or surgical resection.

• Population 1: Patients after primary treatment (radiation therapy and/or surgery) with suspicion of recurrence on magnetic resonance imaging (MRI). Three sub-populations will be considered:

• Recurrent metastatic lesions.

• Recurrent high-grade gliomas (grades 3 and 4).

• Recurrent low-grade gliomas (grades 1 and 2).

• Population 2: Patients prior to primary treatment with planned biopsy or surgical resection.

Exclusion Criteria:

• Patient with known incompatibility to PET or computed tomography (CT)/MRI scans.

• Patient unlikely to comply with study procedures, restrictions and requirements and judged by the investigator to be unsuitable for study participation.

• Sedation or anesthesia can be used for patients who cannot tolerate the exam.